A new proteasome inhibitor, TP-110, induces apoptosis in human prostate cancer PC-3 cells
Isao Momose1, Masatomi Iijima, Manabu Kawada
1Numazu Bio-Medical Research Institute, Microbial Chemistry Research Center, Numazu, Shizuoka, Japan. imomose@bikaken.or.jp
Abstract:
Proteasome inhibitors are useful in the treatment of cancer. Recently, we found a new proteasome inhibitor, TP-110, derived from tyropeptin A produced by Kitasatospora sp. Here we report that TP-110 induces apoptosis in human prostate cancer PC-3 cells. TP-110 showed strong cytotoxicity to PC-3 cells (IC(50)=0.05 muM). It increased the number of cells in the G(2)-M phase and increased the accumulated amounts of the p21 and p27 proteins, which are negative regulators of cell cycle progression. Furthermore, it induced apoptosis along with chromatin condensation and DNA fragmentation in PC-3 cells, and TP-110-induced apoptosis appeared to be associated with caspase activation. Additionally, TP-110 inhibited not only the degradation of IkappaB and the nuclear translocation of nuclear factor-kappaB (NF-kappaB), but also the DNA binding activity of NF-kappaB. These results indicate that TP-110 shows a strong growth inhibition and apoptosis in PC-3 cells.
Insights
A novel proteasome inhibitor, TP-110, effectively induces apoptosis and inhibits growth in human prostate cancer PC-3 cells. This compound demonstrates significant cytotoxicity and impacts cell cycle regulation and nuclear factor-kappaB (NF-kappaB) signaling.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Proteasome inhibitors are established cancer therapeutics.
- Tyropeptin A, produced by Kitasatospora sp., is a source of novel anticancer compounds.
- Prostate cancer remains a significant health concern, necessitating new treatment strategies.
Purpose of the Study:
- To investigate the anticancer effects of TP-110, a novel proteasome inhibitor, on human prostate cancer PC-3 cells.
- To elucidate the mechanisms underlying TP-110's action, including its impact on cell cycle and apoptosis.
- To assess TP-110's effect on nuclear factor-kappaB (NF-kappaB) signaling pathway.
Main Methods:
- Cytotoxicity assays to determine the IC(50) of TP-110 in PC-3 cells.
- Flow cytometry to analyze cell cycle distribution (G(2)-M phase).
- Western blotting to measure protein levels (p21, p27, IkappaB).
- Apoptosis assays (chromatin condensation, DNA fragmentation) and caspase activation assessment.
- Electrophoretic mobility shift assays (EMSA) to evaluate NF-kappaB DNA binding activity.
Main Results:
- TP-110 exhibited potent cytotoxicity against PC-3 cells with an IC(50) of 0.05 muM.
- TP-110 treatment led to G(2)-M phase arrest and increased levels of p21 and p27 proteins.
- Induction of apoptosis, characterized by chromatin condensation and DNA fragmentation, was observed, associated with caspase activation.
- TP-110 inhibited IkappaB degradation, NF-kappaB nuclear translocation, and DNA binding activity.
Conclusions:
- TP-110 demonstrates significant growth inhibition and apoptosis-inducing capabilities in human prostate cancer PC-3 cells.
- The mechanism involves cell cycle arrest, modulation of cell cycle regulators, and inhibition of the NF-kappaB pathway.
- TP-110 represents a promising candidate for further development as a prostate cancer therapeutic.
